KRAS and neoplasm: In this study, we prospectively analyzed a group of 88 patients newly diagnosed with PDAC, applied and validated a method that combines ARMS with HRMA to detect KRAS mutations in both tumor and plasma samples, and showed that having a mutation G12D or G12C in tumor or plasma is associated with lower PFS and OS.